NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company

Executive Summary

• NetraMark Holdings Inc. secured a new, discrete Phase 3 clinical trial analytics contract with a prominent global biopharmaceutical company under an existing master services agreement.
• The engagement expands NetraMark’s AI‑driven decision‑support services into high‑value late‑stage trials, highlighting growing adoption of its NetraAI platform.
• Management cites the win as evidence of increasing trust and momentum for NetraMark’s explainable AI technology in the pharmaceutical industry.

Key Details

• Contract Scope: Provide analytics using NetraAI to identify and characterize patient subpopulations (responders, non‑responders, placebo‑associated) based on screening and baseline variables from a pivotal Phase 3 trial.
• Deliverables: Generate explainable personas and analytical models to aid the sponsor in interpreting differential response patterns, sources of variability, and overall trial outcomes for regulatory and commercial planning.
• Business Impact: Represents repeat business from the same sponsor, indicating satisfaction with prior engagements and reinforcing NetraMark’s presence in Phase 3 programs.
• Strategic Significance: Demonstrates expansion of NetraMark’s role from earlier‑stage support into late‑stage decision making, potentially increasing revenue streams and embedding the platform within biopharma standard operating procedures.
• CEO Quote (George Achilleos): Emphasized momentum, growing trust from sponsors, and the suitability of NetraAI for small, complex datasets typical of late‑stage trials.

Notable Quotes

“Momentum continues to build for NetraMark as more biopharmaceutical companies recognize the value that explainable AI can bring to high‑stakes development programs… Being selected for another project under an existing master services agreement—this time for a pivotal Phase 3 trial—demonstrates the growing trust and confidence that sponsors place in NetraAI.” – George Achilleos, CEO

All forward‑looking statements are subject to risks and uncertainties detailed in NetraMark’s filings with Canadian securities regulators.